ADAPs Drug Pricing Program Public Comments

BACK TO ADAP MAIN POLICY PAGE

• RE: Written comment to the Florida Department of Health expressing opposition to proposed changes set forth in the Notice of Proposed Rule (NPR) #30517381 (March 2, 2026)

• RE: Written comment to Members of the North Carolina Congressional Delegation expressing opposition to HIV federal funding cuts (March 19, 2025)

• RE: Written testimony to the Texas HIV Medication Advisory Committee in support of expanding the Texas AIDS Drug Assistance Program formulary to include Cabenuva (cabotegravir/rilpivirine) (July 9, 2024)

• RE: HIV Community Concerns Over S.4395 (August 15, 2022)

• RE: Needed Update to the Guide for HIV/AIDS Clinical Care for visceral adipose tissue (VAT) (November 21, 2016)

• RE: Federal Register [FR Doc No: 2014-­‐06081] on the Patient Protection and Affordable Care Act; Third Party Payment of Qualified Health Plan Premiums (April 1, 2014)

• RE: Federal Register Volume 79, Number 2 [FR Doc No: 2013-­‐31473] on the Affordable Care Act (ACA) (February 10, 2014)

• RE: Federal Register 77 FR 800: Proposed Data Collection (February 22, 2012)

• RE: ADAP Waiting List Crisis Letter; Mr. Jeffrey Crowley, Director, Office of National AIDS Policy (January 31, 2011)

BACK TO ADAP MAIN POLICY PAGE